Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDrugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares

Financial Services Shell Companies
PortfolioPortfolio WatchlistWatchlist
Company price
10.89 USD 0.00(0%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1207
Market Cap
355.38M
P/E
55.47

Momentum Score

…

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.88
Low
10.89
High
52 Week Price Range
10.04
Low
10.55
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Drugs Made In America Acquisition Corp. is a special purpose acquisition company formed to identify and combine with businesses in or related to U.S. pharmaceutical manufacturing. Long-term growth drivers include rising emphasis on domestic drug production, supply‑chain resilience, and potential government incentives for onshoring; investors may find the vehicle attractive as a way to gain public-market exposure to consolidation or scaling of U.S.-based drug manufacturing.
The main investment risk is that as a blank‑check company it currently has no operating revenues and depends on completing a qualifying business combination, exposing holders to deal execution risk, sponsor conflicts, regulatory scrutiny and market volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
10.89
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-2.71
ROE
-
Net Debt
-0.01M
ROCE
-1.18%
Diluted EPS TTM
0.19

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Income before tax 5.94M -0.00M
Net income 5.94M -0.00M
Selling general administrative 2.82M 0.00M
Ebitda -2.82M -
Depreciation and amortization - 0.00M
Operating income -2.82M -0.00M
Other operating expenses 2.82M 0.00M
Interest income 8.76M -
Net interest income 8.76M -
Total revenue 0.00M -
Total operating expenses 2.82M 0.00M
Total other income expense net 8.76M -
Net income from continuing ops 5.94M -
Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Total assets 239.92M 0.00M
Other current assets 0.01M 0.00M
Total liab 7.28M 0.00M
Total stockholder equity 232.64M -0.00M
Other current liab 0.15M 0.00M
Common stock 239.91M 0.00M
Capital stock 239.91M 0.00M
Retained earnings -7.27M -0.00M
Other assets - -0.00M
Cash 0.01M 0.00M
Total current liabilities 0.38M 0.00M
Net debt -0.01M 0.00M
Short term debt - 0.00M
Short long term debt - 0.66M
Short long term debt total - 0.00M
Other stockholder equity - -0.00M
Total current assets 0.01M 0.00M
Short term investments - 0.00M
Accounts payable 0.22M 0.08M
Non currrent assets other 239.91M 0.00M
Non current assets total 239.91M 0.00M
Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Total cashflows from investing activities -231.15M -
Net borrowings -0.90M -
Total cash from financing activities 231.69M 0.17M
Net income 3.97M -0.00M
Change in cash 0.00M 0.00M
Begin period cash flow 0.00M -
End period cash flow 0.01M 0.00M
Total cash from operating activities -0.54M -0.17M
Issuance of capital stock 232.05M -
Other cashflows from investing activities -231.15M -
Other cashflows from financing activities 0.54M -
Capital expenditures 0.00M 0.00M
Change in working capital 0.14M 0.00M
Other non cash items -4.65M -0.17M
Free cash flow -0.54M -0.00M

Peer Comparison*

Sector: Financial Services Industry: Shell Companies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
DMAA
Drugs Made In America Acquisition Corp. Ordinary Shares		 -
-%		 10.89 55.47 - - 1.53
CLUS
CLUS		 -
-%		 200.00 - - 0.09 0.92
SGDH
Sgd Holdings Ltd		 -
-%		 0.11 - - 59741.55 0.56
LION
Lionsgate Studios Holding Corp. 		0.05
0.35%		 14.29 - 23.31 1.13 1.35
QKIE
QKIE		 0.07
3.72%		 1.95 - - 470.20 -

Profile*

Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.

1 East Broward Boulevard, Fort Lauderdale, FL, United States, 33301

954 870 3099

https://dmaacorp.com

Name Title Year Born
Mr. Roger Bendelac Chief Executive Officer 1957

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…